NASDAQ OMX

Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement

Dela

Alliance to focus on regulatory approval, commercialization and marketing of novel apabetalone therapy in Israel

CALGARY, Alberta, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that it has entered into a licensing agreement with Medison Pharma Ltd. ("Medison") for the Company's lead therapeutic candidate, apabetalone (RVX-208), in Israel and the Palestine Authority. Apabetalone is currently in development for the treatment of high-risk cardiovascular disease (CVD) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), and potential expanded indications.

Under the terms of the agreement, Medison has the exclusive rights to distribute and market apabetalone in Israel. Resverlogix is eligible to receive from Medison, ascending double digit royalties based on future net sales of the product in the region. If certain sales milestones are reached total royalty payments are estimated to potentially reach in excess of US$100 million over the entire patent life in the region.  Medison will be responsible for all regulatory, sales and marketing costs for apabetalone in the Israel region.

"This partnership with Medison is an important validation for our lead molecule apabetalone and our BET inhibition technology," stated Donald McCaffrey, President and CEO of Resverlogix. "Patients in Israel have access to an innovative world class health care system. Having Medison as a leading partner is instrumental in the commercialization and marketing of apabetalone for the many high-risk vascular disease patients in the Israel national health system," McCaffrey added.

"Apabetalone represents a potential new and important therapeutic approach to risk reduction for areas of critical unmet need in Israel such as CVD, diabetes, and  CKD. We look forward to the continued clinical success of apabetalone and working with Resverlogix in fulfilling Medison's vision to provide innovative treatments to patients in Israel," stated Meir Jakobsohn, CEO and founder of Medison.

"Israel represents an important market for medical innovation," stated Kenneth Lebioda, Senior Vice President of Business and Corporate Development at Resverlogix. "We will continue to work closely and strengthen our ongoing collaboration with Medison to ensure successful regulatory approval and commercialization of apabetalone in Israel," Mr. Lebioda added.

About Medison

Medison is Israel's leading marketing group, representing innovative niche healthcare solutions to companies such as Biogen, Amgen, Shire and Ipsen. Employing a comprehensive approach to sales and service, Medison supplies and maintains long-standing relations with HMOs (Health Maintenance Organizations), local medical centers and physicians. Backed by three generations of experience in the healthcare industry since 1937, Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli healthcare market.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx)

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to estimated royalty payments pursuant to the licensing agreement with Medison, the Company's Phase 3 clinical trial and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis,   neurodegenerative disease , Fabry disease,   peripheral artery disease   and other Orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at   www.sedar.com . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Resverlogix Corp via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa19.1.2018 14:00Pressmeddelande

Open Label Extension Results, which Demonstrate Significant Improvements in HS Patients Previously Treated with Placebo, will be Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) AUSTIN, Texas, Jan. 19, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that results from an open label extension (OLE) phase of the randomized Phase 2 study evaluating XBiotech's True Human(TM) antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS), will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference occurring in Rotterdam Netherlands February 7-9th. The oral presentation titled, "An open-label extension study of MABp1 targeting interleukin-1alpha for hidradenitis suppurativa (HS)" will be given by Theodora Kanni, M.D., Ph.D., Attikon University Hospital in Athens Greece, on 8 February 2018 between 1:50 and 2:50pm local time. The findings being presented come from patients that had received placebo in

The Search for #AconfidentYou Role Models Kicks Off at the Xehar Fashion Fairies Conference19.1.2018 12:00Pressmeddelande

Expanding their Fashion Fairies Program, Xehar Teaches and Inspires Women Through Confidence EL SEGUNDO, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Today, the Xehar team announces the Xehar Fashion Fairies Conference, which takes place over three days in Los Angeles, January 19th-21st. The conference gathers aspiring fashionistas to celebrate self love, natural beauty, and learn what it takes inspire women to be more confident. With powerful keynotes, exciting breakout sessions, a fashion show and international networking opportunities, the conference is a unique blend that is new to the fashion industry. "We are searching for our 2018 Fashion Fairies who are serious about a career in fashion and want to inspire women worldwide," says Hadari Oshri, founder and CEO of Xehar. "Attendees will learn how to become one of our exclusive #AconfidentYou Fashion Fairies." Propelled by the successful launch of its existing influencer outreach, Xehar has now expanded their Fashion Fairies program t

Olympus Labs Partners with Leading Korean Fintech Company Metaps Plus19.1.2018 00:03Pressmeddelande

Gibraltar, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Olympus Labs is quickly becoming an emerging global leader in the cryptocurrency-based financial product space, and on the heels of a successful token sale, Olympus is partnering with Seoul-based corporation Metaps Plus, a leading Korean fintech company and mobile marketing platform developer. This news comes shortly after the company announced OKEx, as its official exchange for the company's token MOT. "This is an amazing partnership for us, as it will allow us to hit the Korean market in a big way. We will be able to tap directly into the tens of millions of users on the Metaps Plus platform, allowing users to access financial products created by Olympus," said Kai Chen, CEO of Olympus Labs. "This is a key milestone as it demonstrates that Olympus products can be integrated in third party platforms such as mobile apps, wallets, exchanges, and even physical atms and pos systems, allowing users throughout the world access to Olympus products

Forward Industries Acquires Intelligent Product Solutions18.1.2018 23:54Pressmeddelande

WEST PALM BEACH, Fla. and HAUPPAUGE, N.Y., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Forward Industries (NASDAQ:FORD) today announced the acquisition of Intelligent Product Solutions (IPS), an industry leading product design and development company based in Long Island, New York for a material consideration comprising of cash, equity, and contingent earn outs. IPS clients include leading brands in consumer electronics, medical devices, enterprise and security solution providers and Internet of Things connected solutions, including Google, Physio Control, PepsiCo, Motorola, ABInBev, Zebra and Charity Water. Commenting on the transaction, Terry Wise, CEO of Forward Industries remarked, "I am delighted and excited with the acquisition of IPS. The company is an excellent strategic fit for Forward Industries. Its expertise and strong track record in designing connected/IOT products and developing products such as the AdhereTech 'smart' pill bottle will significantly strengthen and contribute to For

VITEC to Highlight EZ TV IPTV and Digital Signage Platform in First ISE Appearance18.1.2018 21:06Pressmeddelande

PARIS, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In its first-ever attendance at Integrated Systems Europe (ISE), VITEC, a worldwide leader in advanced video encoding and streaming solutions, will showcase EZ TV - a market-leading, broadcast-grade IPTV and digital signage platform with key installations in Europe and the U.S. Targeted to enterprises, sports stadiums and arenas, and government agencies, EZ TV combines low-latency, broadcast-quality IPTV distribution with powerful digital signage capabilities to give audiences a more engaging and interactive experience. "As Europe's largest show for AV systems integrators, ISE is the perfect forum for us to present our EZ TV IPTV platform," said Bruno Teissier, sales and marketing director, VITEC. "We're looking forward to showing ISE attendees how they can help their customers distribute broadcast-quality IPTV content and access powerful digital signage capabilities in an all-in-one, integrated solution." Designed to integrate seamlessly with a

Brookfield Asset Management Notice of 2017 Year End Results Conference Call and Webcast18.1.2018 16:12Pressmeddelande

Date: Thursday, February 15, 2018 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, News, Jan. 18, 2018 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Year End Results Conference Call & Webcast on Thursday, February 15, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on February 15th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-521-4909 toll free in North America, or for overseas calls please dial 1-647-427-2311 at approximately 10:50 a.m. The Conference Call will also be Webcast live at https://event.on24.com/wcc/r/1585364/9F53C4FB4A83FF2D32296C84535D6A34. For those unable to participate

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum